Login to Your Account



Oculus Spinout Ruthigen Focusing on Infection Drug

By Catherine Shaffer
Staff Writer

Monday, January 14, 2013
Oculus Innovative Sciences Inc., of Petaluma, Calif., spun out a new biotechnology business to develop a drug candidate for infection in trauma and surgical procedures. The company, named Ruthigen Inc., will be headed by Hoji Alimi, the current CEO of Oculus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription